The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Bristol-Myers Squibb Co

NYSE: BMY
Last

(U.S.) $67.50

Today's change0.00 0.00%
Updated July 6 4:03 PM EDT. Delayed by at least 15 minutes.
 

Bristol-Myers Squibb Co

NYSE: BMY
Last

(U.S.) $67.50

Today's change0.00 0.00%
Updated July 6 4:03 PM EDT. Delayed by at least 15 minutes.

Bristol-Myers Squibb Co closed at (U.S.)$67.50.

Over the last five days, shares have gained 2.32% and are currently 3.38% off of the 52-week high. Shares have outperformed the S&P 500 by 35.15% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $67.50
  • High--
  • Low--
  • Bid / Ask(U.S.) $66.37 / (U.S.) $71.50
  • YTD % change+14.35%
  • Volume0
  • Average volume (10-day)6,850,411
  • Average volume (1-month)6,516,152
  • Average volume (3-month)6,761,686
  • 52-week range(U.S.) $47.34 to (U.S.) $69.86
  • Beta0.24
  • Trailing P/E50.12×
  • P/E 1 year forward38.44×
  • Forward PEG2.25×
  • Indicated annual dividend(U.S.) $1.48
  • Dividend yield2.19%
  • Trailing EPS(U.S.) $1.35
Updated July 6 4:03 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+14.23%

Based on its net profit margin of 14.23%, Bristol-Myers Squibb Co is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.00%Sector:HealthcareIndustry:Pharmaceuticals - Diversified
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2015Q4/2014Q3/2014Q2/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014
Revenue4,0414,2583,9213,889
Total other revenue--------
Total revenue4,0414,2583,9213,889
Gross profit3,2283,3232,9502,937
Total cost of revenue813935971952
Total operating expense2,7524,3183,2103,449
Selling / general / administrative1,0291,3641,2001,138
Research & development1,0161,189918958
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)98877192538
Other operating expenses, total-204-47-71-137
Operating income1,289-60711440
Interest income (expense), net non-operating-51-53-50-46
Gain (loss) on sale of assets154-3315-7
Other--------
Income before tax1,448-601,008448
Income after tax1,19927732334
Income tax, total249-87276114
Net income1,18613721333
Total adjustments to net income--------
Net income before extra. items1,18613721333
Minority interest-13-14-11-1
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items1,18613721333
Inc. avail. to common incl. extra. items1,18613721333
Diluted net income1,18613721333
Dilution adjustment--------
Diluted weighted average shares1,6761,6761,6701,669
Diluted EPS excluding extraordinary itemsvalue per share0.710.010.430.20
Dividends per sharevalue per share0.500.370.360.36
Diluted normalized EPSvalue per share0.660.350.350.58